Paratek looks to bolster pneumonia antibiotic Nuzyra with win in post-marketing study
Fierce Pharma
JULY 18, 2024
After its buyout last summer by Novo Holdings and Gurnet Point, Paratek Pharmaceuticals reaffirmed the benefits of its Biomedical Advanced Research and Development Authority (BARDA)-backed Nuzyra w | After its buyout last summer by Novo Holdings and Gurnet Point, Paratek Pharmaceuticals reaffirmed the benefits of its BARDA-backed Nuzyra with a positive (..)
Let's personalize your content